Abstract:The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.

Bifunctional small molecules that mediate the degradation of extracellular proteins

Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells

Targeted protein degradation directly engaging lysosomes or proteasomes

Targeted protein degradation in drug development: Recent advances and future challenges

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Targeted protein degradation: mechanisms, strategies and application

Recent advances in targeted protein degraders as potential therapeutic agents

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Degradation of Extracellular and Membrane Proteins in Targeted Therapy: Status Quo and Quo Vadis.

Targeted protein degradation in mammalian cells: A promising avenue toward future

Targeted protein degradation: advances in drug discovery and clinical practice

Targeted protein degradation: from mechanisms to clinic

Targeted protein degradation: current molecular targets, localization, and strategies

Advancing targeted protein degradation for metabolic diseases therapy

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods

Novel approaches to targeted protein degradation technologies in drug discovery

Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design

Chemically Induced Degradation of Native Proteins by Direct Recruitment to the 26S Proteasome

Beyond Canonical PROTAC: Biological Targeted Protein Degradation (Biotpd)